Peptide-targeted cubosome and hexosome nanoassemblies mitigate mitochondrial dysfunction in a MitoPark model
Abstract
Mitochondrial dysfunction is a primary pathogenic mechanism underlying dopaminergic neuron loss in the nigrostriatal pathway in Parkinson’s disease (PD). To investigate mitochondrion-targeted therapeutic strategies, we utilized the MitoPark mouse model, in which mitochondrial transcription factor A ( Tfam ) is selectively ablated in midbrain dopamine neurons, resulting in progressive neurodegeneration. We designed multifunctional lyotropic liquid crystalline nanoparticles (LCNPs) of the cubosome and hexosome types for noninvasive nose-to-brain delivery. These nanocarriers were engineered with lipids essential for membrane integrity (plasmalogens and ω-3 polyunsaturated fatty acids (PUFAs)) and a nonlamellar structural lipid (monoolein). They coencapsulated the neuroprotective antioxidants ginkgolide B and quercetin. To facilitate neuronal targeting and uptake, the surface of the LCNP was modified by conjugation with pituitary adenylate cyclase-activating polypeptide (PACAP) and a rabies virus glycoprotein (RVG)-derived peptide-oleic acid (RVG-OL) conjugate. In vitro studies using differentiated SH-SY5Y cells subjected to oxidative stress demonstrated that the targeted LNPs enhanced cellular uptake and activated key neuroprotective signaling cascades, including AKT, ERK, and STAT3 phosphorylation. In vivo, intranasal administration of the optimized LNPs in MitoPark mice was associated with a trend toward the preservation of dopaminergic neuronal markers (such as tyrosine hydroxylase) and the regulation of mitochondrial-related proteins such as ATP5A1. Transcriptomic profiling revealed extensive molecular reprogramming. The peptide-functionalized LNPs upregulated genes enriched in mitochondrial biogenesis ( Ppargc1a and Pink1 ) and survival ( Bcl2 ) but downregulated the expression of neuroinflammatory mediators ( Il6 , Nos2, Myd88, and Trem2 ) and apoptotic effectors. These findings establish peptide-targeted, therapeutic lipid (plasmalogen/PUFA)-based nanoassemblies as a potent nonviral platform for noninvasive nose-to-brain delivery that may modulate mitochondrial- and neurodegeneration-related signaling pathways in a genetic model of PD.
Related
- A Fluorescent Pillarplex Rotaxane as a Modular Supramolecular Organometallic Platform for Nanoassemblies
- Cubosome integrated with polymeric carbon nitride and cisplatin: in vivo biodistribution and in vitro photodynamic therapy studies.
- Environmentally relevant PFBS exposure triggers colonic inflammation through PPAR-mediated mitochondrial dysfunction and cGAS–STING activation
- Metabolic and Immunometabolic Neuroprotection in Glaucoma: Mitochondrial Dysfunction, Neuroinflammation, and Emerging Therapeutic Strategies
- Spatiotemporally stratified nanoassemblies for precisely halting the immunothrombotic vicious cycle in acute lung inflammation
BibTeX
@article{akanchise2026peptidetargeted,
title = {{Peptide-targeted cubosome and hexosome nanoassemblies mitigate mitochondrial dysfunction in a MitoPark model}},
author = {Thelma Akanchise and Fucen Luo and Borislav Angelov and Yuru Deng and Takehiko Fujino and Angelina Angelova},
journal = {Signal Transduction and Targeted Therapy},
year = {2026},
month = aug,
doi = {10.1038/s41392-026-02897-w},
url = {https://hal.science/hal-05843638v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peptide-targeted cubosome and hexosome nanoassemblies mitigate mitochondrial dysfunction in a MitoPark model
AU - Thelma Akanchise
AU - Fucen Luo
AU - Borislav Angelov
AU - Yuru Deng
AU - Takehiko Fujino
AU - Angelina Angelova
PY - 2026
DA - 2026/08/04
JO - Signal Transduction and Targeted Therapy
DO - 10.1038/s41392-026-02897-w
UR - https://hal.science/hal-05843638v1
AB - Mitochondrial dysfunction is a primary pathogenic mechanism underlying dopaminergic neuron loss in the nigrostriatal pathway in Parkinson’s disease (PD). To investigate mitochondrion-targeted therapeutic strategies, we utilized the MitoPark mouse model, in which mitochondrial transcription factor A ( Tfam ) is selectively ablated in midbrain dopamine neurons, resulting in progressive neurodegeneration. We designed multifunctional lyotropic liquid crystalline nanoparticles (LCNPs) of the cubosome and hexosome types for noninvasive nose-to-brain delivery. These nanocarriers were engineered with lipids essential for membrane integrity (plasmalogens and ω-3 polyunsaturated fatty acids (PUFAs)) and a nonlamellar structural lipid (monoolein). They coencapsulated the neuroprotective antioxidants ginkgolide B and quercetin. To facilitate neuronal targeting and uptake, the surface of the LCNP was modified by conjugation with pituitary adenylate cyclase-activating polypeptide (PACAP) and a rabies virus glycoprotein (RVG)-derived peptide-oleic acid (RVG-OL) conjugate. In vitro studies using differentiated SH-SY5Y cells subjected to oxidative stress demonstrated that the targeted LNPs enhanced cellular uptake and activated key neuroprotective signaling cascades, including AKT, ERK, and STAT3 phosphorylation. In vivo, intranasal administration of the optimized LNPs in MitoPark mice was associated with a trend toward the preservation of dopaminergic neuronal markers (such as tyrosine hydroxylase) and the regulation of mitochondrial-related proteins such as ATP5A1. Transcriptomic profiling revealed extensive molecular reprogramming. The peptide-functionalized LNPs upregulated genes enriched in mitochondrial biogenesis ( Ppargc1a and Pink1 ) and survival ( Bcl2 ) but downregulated the expression of neuroinflammatory mediators ( Il6 , Nos2, Myd88, and Trem2 ) and apoptotic effectors. These findings establish peptide-targeted, therapeutic lipid (plasmalogen/PUFA)-based nanoassemblies as a potent nonviral platform for noninvasive nose-to-brain delivery that may modulate mitochondrial- and neurodegeneration-related signaling pathways in a genetic model of PD.
SN - 2095-9907
SN - 2059-3635
ER -